RxDoctor Payments Data

Lauren Bogdan, MD

Otolaryngology · Wilmington, DENPI 1659767028

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $637, 5.6 times the $115 reported in 2021. That places this record below the midpoint for otolaryngology clinicians in DE, where the typical reported total is $1,648.

$1,648in general payments, 2019–2025

Across 78 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$333
  • CSL Behring$303
  • Takeda Pharmaceuticals U.S.A., Inc.$156
  • Biocryst US Sales Co., LLC$121
  • Genentech USA, Inc.$106
  • Sanofi$91
  • plus $538 from 17 others

What the payments were for

  • Food & beverage$1,648100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,648 in reported general payments places this provider in the 50th percentile of 27 otolaryngology providers in Delaware.

See all otolaryngology providers in Delaware

Medicare billing

Part B allowed, 2024
$173,791
Medicare patients
839
Services billed
2,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl38$1,440
Ipratropium Bromide34$1,101
Fluticasone Propionate94$951
Omeprazole26$311
Nortriptyline Hcl11$240
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$187
Mupirocin14$86
Methylprednisolone12$75
Prednisone14$37

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →